WESTLAKE VILLAGE, Calif., Sept. 01, 2017 -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for patients with diseases such as diabetes, announced today that it will present at upcoming conferences.
- Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 9:35 am (ET) at the Lotte New York Palace in New York
- Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 9:10 am (ET) at the InterContinental New York Barclay Hotel in New York
Presenting from the Company will be its Chief Executive Officer, Michael Castagna.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com.
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya SVP Investor Relations 818-661-5055 [email protected]


7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Italy Fines Apple €98.6 Million Over App Store Dominance
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 



